252 related articles for article (PubMed ID: 37607000)
1. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.
Zuberi A; Huang Y; Dotts AJ; Wei H; Coon JS; Liu S; Iizuka T; Wu O; Sotos O; Saini P; Chakravarti D; Boyer TG; Dai Y; Bulun SE; Yin P
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37607000
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan 2,3-Dioxygenase-2 in Uterine Leiomyoma: Dysregulation by MED12 Mutation Status.
Hutchinson AP; Yin P; Neale I; Coon JS; Kujawa SA; Liu S; Bulun SE
Reprod Sci; 2022 Mar; 29(3):743-749. PubMed ID: 35064560
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
5. Mono-(2-ethyl-5-hydroxyhexyl) phthalate promotes uterine leiomyoma cell survival through tryptophan-kynurenine-AHR pathway activation.
Iizuka T; Yin P; Zuberi A; Kujawa S; Coon JS; Björvang RD; Damdimopoulou P; Pacyga DC; Strakovsky RS; Flaws JA; Bulun SE
Proc Natl Acad Sci U S A; 2022 Nov; 119(47):e2208886119. PubMed ID: 36375056
[TBL] [Abstract][Full Text] [Related]
6. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
7. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
8. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
9. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
10. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
11. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
12. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
13. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
14. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
15. EWS-FLI1 impairs aryl hydrocarbon receptor activation by blocking tryptophan breakdown via the kynurenine pathway.
Mutz CN; Schwentner R; Kauer MO; Katschnig AM; Kromp F; Aryee DN; Erhardt S; Goiny M; Alonso J; Fuchs D; Kovar H
FEBS Lett; 2016 Jul; 590(14):2063-75. PubMed ID: 27282934
[TBL] [Abstract][Full Text] [Related]
16. Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell.
El Andaloussi A; Al-Hendy A; Ismail N; Boyer TG; Halder SK
Reprod Sci; 2020 Mar; 27(3):823-832. PubMed ID: 32046450
[TBL] [Abstract][Full Text] [Related]
17. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.
Moyo MB; Parker JB; Chakravarti D
Nat Commun; 2020 Feb; 11(1):1019. PubMed ID: 32094355
[TBL] [Abstract][Full Text] [Related]
18. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
20. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Novikov O; Wang Z; Stanford EA; Parks AJ; Ramirez-Cardenas A; Landesman E; Laklouk I; Sarita-Reyes C; Gusenleitner D; Li A; Monti S; Manteiga S; Lee K; Sherr DH
Mol Pharmacol; 2016 Nov; 90(5):674-688. PubMed ID: 27573671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]